4SC is a drug discovery and development company that uses its cheminformatics-based technology platform for the discovery and development of new drug candidates for the treatment of patients suffering from diseases with high medical needs.
Thus, 4SC has been generating a risk-balanced and continuously advancing pipeline of projects. 4SC's therapeutic focus centres on cancer and inflammatory diseases as well as virus infections since these indications combine significant market potential and high medical needs with reasonable development time and cost in the early clinical stages. 
The first project on the treatment of rheumatoid arthritis has completed clinical phase IIa. Additional projects in research and pre-clinical stages are progressing towards clinical development. All of 4SC's pipeline projects have been generated by 4SC's proprietary technology platform.
4SC aims to realise the commercial potential of these programmes through licensing arrangements with pharmaceutical partners.
4SC's technology platform combines the disciplines of chemistry and biology with the proprietary virtual High Throughput Screening technology, 4SCan®. This technology has transferred the principle of traditional High Throughput Screening from the laboratory to the computer. The integration of this in silico screening method into a seamless drug discovery and development workflow allows a significant reduction of development times from the identification of active molecules through to proof-of-concept in clinical trials. The cost and risk involved in bringing a drug to market are thus reduced.
The company was founded in 1997 and has its premises in Planegg-Martinsried, Germany. 4SC has been listed in the Prime Standard Segment (regulated market) of the Frankfurt Stock Exchange since December 15, 2005.

URL: http://www.4sc.de